Converting monoclonal antibody-based immunotherapies from passive to active: bringing immune complexes into play.
Converting monoclonal antibody-based immunotherapies from passive to active: bringing immune complexes into play.
复制标题
DOI：
10.1038/emi.2016.97
复制
发表时间：
2016-08-17
影响因子：
13.2
通讯作者：
Pelegrin, Mireia
中科院分区：
文献类型：
--
作者：
Lambour, Jennifer;Naranjo-Gomez, Mar;Piechaczyk, Marc;Pelegrin, Mireia
关键词：
目前构成生物疗法主要类别的单抗(MAbs)现在被认为是越来越多地被考虑用于对抗严重病毒感染的主要医学工具。事实上，近年来开发的抗病毒单抗的数量呈指数级增长。尽管它们对病毒钝化的直接作用已被详细研究，但它们潜在的免疫调节作用直到最近才被忽视。抗病毒单抗在受感染的生物体中调节抗病毒免疫反应的能力最近被揭示。更具体地说，在识别其同源抗原后，mAbs形成免疫复合体(IC)，可被感染个体不同免疫细胞上表达的Fc受体识别。这种结合之后可能伴随着宿主免疫反应的调节。利用这种免疫调节特性可能有助于提高抗病毒单抗的治疗潜力。本文从被动免疫治疗和疫苗接种策略两个方面综述了由不同病毒决定簇和单抗形成的ICs在诱导抗病毒免疫反应中的作用。文中还讨论了ICs对宿主免疫反应的潜在有害影响。
Monoclonal antibodies (mAbs), which currently constitute the main class of biotherapeutics, are now recognized as major medical tools that are increasingly being considered to fight severe viral infections. Indeed, the number of antiviral mAbs developed in recent years has grown exponentially. Although their direct effects on viral blunting have been studied in detail, their potential immunomodulatory actions have been overlooked until recently. The ability of antiviral mAbs to modulate antiviral immune responses in infected organisms has recently been revealed. More specifically, upon recognition of their cognate antigens, mAbs form immune complexes (ICs) that can be recognized by the Fc receptors expressed on different immune cells of infected individuals. This binding may be followed by the modulation of the host immune responses. Harnessing this immunomodulatory property may facilitate improvements in the therapeutic potential of antiviral mAbs. This review focuses on the role of ICs formed with different viral determinants and mAbs in the induction of antiviral immune responses in the context of both passive immunotherapies and vaccination strategies. Potential deleterious effects of ICs on the host immune response are also discussed.
登录
查看更多内容
影响因子：
64.5
作者：
Flyak AI;Shen X;Murin CD;Turner HL;David JA;Fusco ML;Lampley R;Kose N;Ilinykh PA;Kuzmina N;Branchizio A;King H;Brown L;Bryan C;Davidson E;Doranz BJ;Slaughter JC;Sapparapu G;Klages C;Ksiazek TG;Saphire EO;Ward AB;Bukreyev A;Crowe JE Jr
通讯作者：
Crowe JE Jr
影响因子：
64.8
作者：
Caskey M;Klein F;Lorenzi JC;Seaman MS;West AP Jr;Buckley N;Kremer G;Nogueira L;Braunschweig M;Scheid JF;Horwitz JA;Shimeliovich I;Ben-Avraham S;Witmer-Pack M;Platten M;Lehmann C;Burke LA;Hawthorne T;Gorelick RJ;Walker BD;Keler T;Gulick RM;Fätkenheuer G;Schlesinger SJ;Nussenzweig MC
通讯作者：
Nussenzweig MC
影响因子：
25.7
作者：
Bengsch, Bertram;Martin, Bianca;Thimme, Robert
通讯作者：
Thimme, Robert
DOI：
10.1073/pnas.1510199112
发表时间：
2015-08-18
影响因子：
11.1
作者：
Corti, Davide;Zhao, Jincun;Lanzavecchia, Antonio
通讯作者：
Lanzavecchia, Antonio
大致中和抗体消除了乙型肝炎病毒感染。
影响因子：
17.1
作者：
de Jong YP;Dorner M;Mommersteeg MC;Xiao JW;Balazs AB;Robbins JB;Winer BY;Gerges S;Vega K;Labitt RN;Donovan BM;Giang E;Krishnan A;Chiriboga L;Charlton MR;Burton DR;Baltimore D;Law M;Rice CM;Ploss A
通讯作者：
Ploss A